The immune system is built to communicate.

Our mission is to listen.

​

MeMed listens to the language of the body to solve big problems of 21st century medicine.

Highlights:

New study using MeMed Key finds rapid quantification of immune biomarker IP-10 could support personalized treatment of severe COVID-19. Results published in PLOS One.

The Era of Deep Listening has begun

MeMed listens and decodes the complex signals of the human body, our Host-Response system - into actionable insights to help physicians make better informed decisions for their patients. 

The Test: MeMed BV™ 

​

MeMed BV™ - a pioneering test for distinguishing between bacterial and viral infections that relies on the most accurate detection system - the body's immune system. MeMed BV™ aims to support physicians in making better informed antibiotic treatment decisions and tackling antimicrobial resistance - one of the biggest healthcare challenges of our time.

The Platform: MeMed Key™

MeMed Key™  is a first of its kind immunoassay platform that opens the way to measuring multiple proteins with central lab performance at the point-of-need.  MeMed Key™ can run the MeMed BV™ test within 15 minutes.

The Evidence:

MeMed’s signature has been validated by real-world data from over 20,000 patients and multinational, double-blind clinical studies, published in peer-reviewed journals.

In the news:

MeMed Named "Technology Pioneer" by World Economic Forum

A new blood test could stop doctors from over prescribing antibiotics

Inflammatory Biomarker Tests for Guiding COVID-19 Treatment

We're Growing

If you are a top tier professional and a team player we would be happy to hear from you. Check out our current open positions.

Contact Us